series-c-plus
Stage
2
Investors
About
Pulmocide is a biopharmaceutical company developing inhaled therapies for serious respiratory diseases, primarily focusing on treating invasive pulmonary aspergillosis with its lead compound opelconazole, which is currently in Phase 3 clinical trials.
Explore Pulmocide's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.